BackEcho Therapeutics Overview

Echo Therapeutics Gross Profit

Latest gross profit for ECTE: $0, below the sector sector average of $660M.

Get informed when a big investor buys or sells

+ Follow

Quarterly Gross Profit

N/A

As of Sep 30, 2016

Annual Gross Profit (TTM)

N/A

Trailing 12 months ending Sep 30, 2016

Average Gross Profit (Comparison Companies)

Gross Profit History

Gross Profit Comparison

Annual Gross Profit Growth Rate (%)

Annual Gross Profit Growth (Absolute)

Echo Therapeutics (ECTE) FAQ

Echo Therapeutics posts a gross profit of $0 as of September 2016. In the prior-year period, the figure was $0. That is below the sector sector average of $660M. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Echo Therapeutics's gross profit was $0. The latest reading is $0 (period ending September 2016). Use the history and growth charts on this page for a longer lookback.

For its sector stocks, a gross profit near $660M is typical. Echo Therapeutics's $0 is lower that level. That is roughly 100.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Gross Profit is one piece of Echo Therapeutics's financial statement story. At $0, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for ECTE's gross profit usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $660M), and (3) consistency with growth and profitability. This page covers the first two; Echo Therapeutics's other metric pages and overview cover the third.